Repository logo
 
Publication

Nanocarriers in Tuberculosis treatment: Challenges and delivery strategies

2023-09-26Journal article Open access
Simple item page
dc.contributor.authorKumar, Mahesh
dc.contributor.authorVirmani, Tarun
dc.contributor.authorKumar, Girish
dc.contributor.authorDeshmukh, Rohitas
dc.contributor.authorSharma, Ashwani
dc.contributor.authorDuarte, Sofia
dc.contributor.authorBrandão, Pedro
dc.contributor.authorFonte, Pedro
dc.date.accessioned2023-10-30T14:46:35Z
dc.date.available2023-10-30T14:46:35Z
dc.date.issued2023-09-26
dc.date.updated2023-10-27T10:26:53Z
dc.description.abstractThe World Health Organization identifies tuberculosis (TB), caused by Mycobacterium tuberculosis, as a leading infectious killer. Although conventional treatments for TB exist, they come with challenges such as a heavy pill regimen, prolonged treatment duration, and a strict schedule, leading to multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains. The rise of MDR strains endangers future TB control. Despite these concerns, the hunt for an efficient treatment continues. One breakthrough has been the use of nanotechnology in medicines, presenting a novel approach for TB treatment. Nanocarriers, such as lipid nanoparticles, nanosuspensions, liposomes, and polymeric micelles, facilitate targeted delivery of anti-TB drugs. The benefits of nanocarriers include reduced drug doses, fewer side effects, improved drug solubility, better bioavailability, and improved patient compliance, speeding up recovery. Additionally, nanocarriers can be made even more targeted by linking them with ligands such as mannose or hyaluronic acid. This review explores these innovative TB treatments, including studies on nanocarriers containing anti-TB drugs and related patents.pt_PT
dc.description.sponsorshipLA/P/0101/2020; LA/P/0140/2020;pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationPharmaceuticals 16 (10): 1360 (2023)pt_PT
dc.identifier.doi10.3390/ph16101360pt_PT
dc.identifier.eissn1424-8247
dc.identifier.urihttp://hdl.handle.net/10400.1/20109
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMDPIpt_PT
dc.relationAlgarve Centre for Marine Sciences
dc.relationAlgarve Centre for Marine Sciences
dc.relationInstitute for Bioengineering and Biosciences
dc.relationInstitute for Bioengineering and Biosciences
dc.relationEgas Moniz Interdisciplinary Research Center
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectTuberculosispt_PT
dc.subjectLigandpt_PT
dc.subjectNanoformulationpt_PT
dc.subjectNanoparticlept_PT
dc.subjectPatentpt_PT
dc.subjectMannosept_PT
dc.subjectFolic acidpt_PT
dc.titleNanocarriers in Tuberculosis treatment: Challenges and delivery strategiespt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleAlgarve Centre for Marine Sciences
oaire.awardTitleAlgarve Centre for Marine Sciences
oaire.awardTitleInstitute for Bioengineering and Biosciences
oaire.awardTitleInstitute for Bioengineering and Biosciences
oaire.awardTitleEgas Moniz Interdisciplinary Research Center
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F04326%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP%2F04326%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F04565%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP%2F04565%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F04585%2F2020/PT
oaire.citation.issue10pt_PT
oaire.citation.startPage1360pt_PT
oaire.citation.titlePharmaceuticalspt_PT
oaire.citation.volume16pt_PT
oaire.fundingStream6817 - DCRRNI ID
oaire.fundingStream6817 - DCRRNI ID
oaire.fundingStream6817 - DCRRNI ID
oaire.fundingStream6817 - DCRRNI ID
oaire.fundingStream6817 - DCRRNI ID
person.familyNameFonte
person.givenNamePedro
person.identifier.ciencia-id2410-123D-3385
person.identifier.orcid0000-0002-1115-9282
person.identifier.ridK-3215-2013
person.identifier.scopus-author-id55146900200
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationa5a5c2b2-9112-4bf4-8618-8c2051bbc116
relation.isAuthorOfPublication.latestForDiscoverya5a5c2b2-9112-4bf4-8618-8c2051bbc116
relation.isProjectOfPublicationfafa76a6-2cd2-4a6d-a3c9-772f34d3b91f
relation.isProjectOfPublication15f91d45-e070-47d8-b6b8-efd4de31d9a8
relation.isProjectOfPublication2aa82082-d177-45a7-bcfb-53835259cdf7
relation.isProjectOfPublicationb77fb4c4-29d2-40d6-a038-861ad88968d7
relation.isProjectOfPublication2cd937f3-d3f3-44e6-9fdf-534d27a28b2c
relation.isProjectOfPublication.latestForDiscoveryfafa76a6-2cd2-4a6d-a3c9-772f34d3b91f

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
pharmaceuticals-16-01360-v2.pdf
Size:
6.74 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
3.46 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

CCM2-Artigos (em revistas ou actas indexadas)
FCT2-Artigos (em revistas ou actas indexadas)